| Literature DB >> 32012224 |
Theodor Uden1, Alice Bertaina2, Jonas Abrahamsson3, Marc Ansari4, Adriana Balduzzi5, Jean-Pierre Bourquin6, Corinne Gerhardt7, Marc Bierings7, Henrik Hasle8, Arjan Lankester9, Kirsten Mischke1, Andrew S Moore10, Ian Nivison-Smith11, Anna Pieczonka12, Christina Peters13, Petr Sedlacek14, Dirk Reinhardt15, Jerry Stein16, Birgitta Versluys17, Jacek Wachowiak12, Leen Willems18, Martin Zimmermann1, Franco Locatelli2,19, Martin G Sauer1.
Abstract
Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoietic stem cell transplantation was analyzed. Four-year probability of overall survival (4y-pOS) was 14%. 4y-pOS for 122 children receiving a second haematopoietic stem cell transplantation was 31% and 3% for those that did not (P = <0·0001). Achievement of a subsequent remission impacted survival (P = <0·0001). For patients receiving a second transplant survival with or without achieving a subsequent remission was comparable. Graft source (bone marrow vs. peripheral blood stem cells, P = 0·046) and donor choice (matched family vs. matched unrelated donor, P = 0·029) positively impacted survival after relapse. Disease recurrence and non-relapse mortality at four years reached 45% and 22%.Entities:
Keywords: acute myeloid leukemia; allogeneic hematopoietic stem cell transplantation; children; relapse; second hematopoietic stem cell transplantation
Year: 2020 PMID: 32012224 DOI: 10.1111/bjh.16441
Source DB: PubMed Journal: Br J Haematol ISSN: 0007-1048 Impact factor: 6.998